A weighted sample size for microarray datasets that considers the variability of variance and multiplicity(BIOINFORMATICS)
スポンサーリンク
概要
- 論文の詳細を見る
Microarray experiments are often performed to detect differently expressed genes among different clinical phenotypes. The method used to calculate the appropriate sample size for this purpose differs from the sample size calculation used for general clinical experiments, because microarrays include tens of thousands of genes. We proposed a sample size calculation method that considers variance among an entire gene set and used the Bonferroni correction to address the multiplicity problem. Specifically, by adjusting for the multiplicity problem, the existing equation for sample size calculation was modified based on the Bonferroni correction. By k-means cluster analysis, the variances across all genes can be divided into several groups with similar values, and the sample sizes for each group were subsequently calculated and weight-averaged. The results of this study show that the sample size was related to the number of genes on a chip. The weighted sample size, calculated by the proposed method, preserved the Type I error for selection of significant genes within a microarray data set.
- 公益社団法人日本生物工学会の論文
著者
-
Chung Hyun
Cancer Metastasis Research Center Yonsei University College Of Medicine:brain Korea 21 Project For M
-
Rha Sun
Cancer Metastasis Research Center Yonsei University College Of Medicine:brain Korea 21 Project For M
-
Kim Ki-Yeol
Oral Cancer Research Institute, Yonsei University College of Dentistry
-
Rha Sun
Cancer Metastasis Research Center
-
Kim Ki-yeol
Oral Cancer Research Institute Yonsei University College Of Dentistry
-
Chung Hyun
Cancer Metastasis Research Center
関連論文
- A weighted sample size for microarray datasets that considers the variability of variance and multiplicity(BIOINFORMATICS)
- Chemokine growth-regulated oncogene 1 as a putative biomarker for gastric cancer progression
- Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure : a phase II randomized selection trial